<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Normal immunoglobulin see Immunoglobulins, normal; HNIG see Immunoglobulins, normal; Immunoglobulins: normal; Congenital agammaglobulinaemia, replacement therapy; Agammaglobulinaemia, congenital, replacement therapy; Hypogammaglobulinaemia; Thrombocytopenic purpura: immunoglobulin; Kawasaki syndrome; Guillain-Barré syndrome; Hepatitis A: immunoglobulin, normal; Measles: immunoglobulin, normal; Rubella: immunoglobulin, normal" /><meta name="IX" content="Immunoglobulins: normal; Congenital agammaglobulinaemia, replacement therapy; Agammaglobulinaemia, congenital, replacement therapy; Hypogammaglobulinaemia; Thrombocytopenic purpura: immunoglobulin; Kawasaki syndrome; Guillain-Barré syndrome; Hepatitis A: immunoglobulin, normal; Measles: immunoglobulin, normal; Rubella: immunoglobulin, normal" /><meta name="IXN" content="Normal immunoglobulin see Immunoglobulins, normal; HNIG see Immunoglobulins, normal" /><title>14.5.1 Normal immunoglobulin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP8431-normal-immunoglobulin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP8431-normal-immunoglobulin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP8431-normal-immunoglobulin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8209-immunological-products-and-vaccines.htm">14 Immunological products and vaccines</a> &gt; <a href="PHP8429-immunoglobulins.htm">14.5 Immunoglobulins</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP8429-immunoglobulins.htm" title="Previous: 14.5 Immunoglobulins">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP8436-normal-immunoglobulin.htm" title="Next: NORMAL IMMUNOGLOBULIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>14.5.1 </span>Normal immunoglobulin</h1><?highlighter on?><div id="pC" class="jN"><p>Human <strong>normal immunoglobulin </strong>(‘HNIG’) is prepared from pools of at least 1000 donations of human plasma; it contains immunoglobulin G (IgG) and antibodies to hepatitis A, measles, mumps, rubella, varicella, and other viruses that are currently prevalent in the general population.</p><p id="PHP8432">Normal immunoglobulin may <strong>interfere with the immune response to live virus vaccines</strong> which should therefore only be given <strong>at least 3 weeks before or 3 months after</strong> an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).</p><div><h2>Uses</h2><p>Normal immunoglobulin (containing 10%–18%) is administered by <em>intramuscular injection</em> for the protection of susceptible contacts against <strong>hepatitis A</strong> virus (infectious hepatitis), <strong>measles</strong> and, to a lesser extent, <strong>rubella</strong>. Injection of immunoglobulin produces immediate protection lasting several weeks. </p><p>Normal immunoglobulin (containing 3%–12% protein) for <em>intravenous administration</em> is used as <em>replacement therapy</em> for patients with congenital agammaglobulinaemia and hypogammaglobulinaemia, and for the short-term treatment of idiopathic thrombocytopenic purpura and Kawasaki syndrome; it is also used for the prophylaxis of infection following bone-marrow transplantation and in children with symptomatic HIV infection who have recurrent bacterial infections. Normal immunoglobulin for replacement therapy may also be given intramuscularly or subcutaneously, but intravenous formulations are normally preferred. Intravenous immunoglobulin is also used in the treatment of Guillain-Barré syndrome as an alternative to plasma exchange.</p><p>For guidance on the use of intravenous normal immunoglobulins and alternative therapies for certain conditions, consult <em>Clinical Guidelines for Immunoglobulin Use</em> (<a href="http://www.dh.gov.uk">www.dh.gov.uk</a>).</p></div><div id="PHP8433"><h2>Hepatitis A</h2><p><strong>Hepatitis A vaccine</strong> is preferred for individuals at risk of infection (see <a title="monograph-family: Hepatitis A vaccine" href="PHP8290-hepatitis-a-vaccine.htm">Hepatitis A vaccine</a>) including those visiting areas where the disease is highly endemic (all countries excluding Northern and Western Europe, North America, Japan, Australia, and New Zealand). In unimmunised individuals, transmission of hepatitis A is reduced by good hygiene. Intramuscular normal immunoglobulin is no longer recommended for routine prophylaxis in travellers, but it may be indicated for immunocompromised patients if their antibody response to the vaccine is unlikely to be adequate.</p><p>Intramuscular normal immunoglobulin is recommended for prevention of infection in close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age; normal immunoglobulin should be given as soon as possible, preferably within 14 days of exposure to the primary case. However, normal immunoglobulin can still be given to contacts at risk of severe disease up to 28 days after exposure to the primary case. Hepatitis A vaccine can be given at the same time, but it should be given at a separate injection site.</p></div><div id="PHP8434"><h2>Measles</h2><p>Intravenous or subcutaneous normal immunoglobulin may be given to prevent or attenuate an attack of measles in individuals who do not have adequate immunity. Children and adults with compromised immunity who have come into contact with measles should receive intravenous or subcutaneous normal immunoglobulin as soon as possible after exposure. It is most effective if given within 72 hours but can be effective if given within 6 days.</p><p>Subcutaneous or intramuscular normal immunoglobulin should also be considered for the following individuals if they have been in contact with a confirmed case of measles or with a person associated with a local outbreak:</p><ul><li><p>non-immune pregnant women;</p> </li><li><p>infants under 9 months.</p> </li></ul><p>Further advice should be sought from the Centre for Infections, Health Protection Agency (tel. (020) 8200 6868).</p><p>Individuals with normal immunity who are not in the above categories and who have not been fully immunised against measles, can be given MMR vaccine (<a title="monograph-family: MMR vaccine" href="PHP8346-measles-mumps-and-rubella-mmr-vaccine.htm">section 14.4</a>) for prophylaxis following exposure to measles.</p></div><div id="PHP8435"><h2>Rubella</h2><p>Intramuscular immunoglobulin after exposure to rubella does <strong>not</strong> prevent infection in non-immune contacts and is <strong>not</strong> recommended for protection of pregnant women exposed to rubella. It may, however, reduce the likelihood of a clinical attack which may possibly reduce the risk to the fetus. Risk of intrauterine transmission is greatest in the first 11 weeks of pregnancy, between 16 and 20 weeks there is minimal risk of deafness only, after 20 weeks there is no increased risk. Intramuscular normal immunoglobulin should be used only if termination of pregnancy would be unacceptable to the pregnant woman—it should be given as soon as possible after exposure. Serological follow-up of recipients is essential to determine if the woman has become infected despite receiving immunoglobulin.</p><p>For routine prophylaxis against Rubella, see <a title="monograph-family: Measles, Mumps and Rubella (MMR) vaccine" href="PHP8346-measles-mumps-and-rubella-mmr-vaccine.htm">MMR vaccine</a>.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP8436-normal-immunoglobulin"><a href="PHP8436-normal-immunoglobulin.htm" title="NORMAL IMMUNOGLOBULIN">NORMAL IMMUNOGLOBULIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP8429-immunoglobulins.htm">Previous: 14.5 Immunoglobulins</a> | <a class="top" href="PHP8431-normal-immunoglobulin.htm#">Top</a> | <a accesskey="]" href="PHP8436-normal-immunoglobulin.htm">Next: NORMAL IMMUNOGLOBULIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>